Pfizer, BioNTech begin adapting their vaccine to Covid's Omicron variant

Source : 112 Ukraine

In case of necessity, the new version of the vaccine could appear within 100 days
17:17, 29 November 2021

Open source

Pfizer and BioNTech, the companies that developed one of the most popular vaccines against Covid-19 began to work on the adaptation of their vaccine to the new strain known as Omicron.

"BioNTech said Monday that it has started development in order to move as quickly as possible. The first steps of developing a new vaccine overlap with the research necessary in order to evaluate whether the shot will be needed - a process that both it and Moderna began last Thursday as news of the new variant began to spread around the world", writes Bloomberg.

The outlet claims that in case of necessity, the new version of the vaccine could appear within 100 days.

Related: No severe forms of Omicron Covid-19 strain spotted in South Africa

Earlier, British scientists discovered a new strain of coronavirus - B.1.1.529, which contains 32 mutations in the spike protein. The virus uses this part to enter the cell of the body with its subsequent infection. The characteristics of the B.1.1.529 virus could give rise to serious concern among scientists about the hazard of this strain.

Subsequently, WHO announced that it was organizing a special meeting to discuss the new strain of coronavirus.

The result of the meeting was the name Omicron given to the SARS-CoV-2 coronavirus B.1.1.529 strain with 32 mutations.

Pfizer and BioNTech soon announced a plan to adapt their mRNA vaccine to the new Omicron strain.

A new strain of coronavirus has already been found in the Republic of South Africa, Belgium, Israel, Germany, Italy, Austria, Great Britain.

Related: Japan imposes entry ban for all foreigners due to spread of Omicron strain

Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more